

oncotype DX[®]
Breast Cancer Assay

Personalizing adjuvant therapy decisions in ER+ & HER2- breast cancer

Oncotype DX: Considerations for Patient Selection¹⁻⁶

Tamoxifen or AI ^{3*}	Stage I	pT1 [†] , N0	Included in ASCO [®] and NCCN [®] Guidelines ^{4,5}
		pT2-3, N0	
	Stage II	pT1 [†] -3, N1mi	Included in NCCN Guidelines ^{TM5}
		pT0-2, N1	
	Stage III [‡]	pT3, N1	Certain node positive patients ^{3,6}

Patient selection considerations are based on data from the suite of Oncotype DX studies, including: NSABP B-14, NSABP B-20, TransATAC, and SWOG 8814.^{1-3,6}

*AI=aromatase inhibitor.

[†]>0.5 cm

[‡]Consider patients from a subset of stage IIIa as indicated, not all stage III patients.

Oncotype DX® online portal

- Access your patients' test results and order Oncotype DX online at <https://online.genomichealth.com>

Oncotype DX insurance for patients

- More than 95% of US privately insured lives in node negative breast cancer covered⁷
- Payment by selected payers for patients with micrometastatic disease and node-positive disease
- Genomic Access Program (GAP) and Financial Assistance Program (FAP) broadens access based on patient's financial eligibility

Oncotype DX Customer Service/Reimbursement

You can contact Genomic Health at 1-866-ONCOTYPE (1-866-662-6897) or by e-mail at customerservice@genomichealth.com.

www.oncotypedx.com

References: **1.** Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004;351:2817-2826. **2.** Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.* 2006;24(23):3726-3734. **3.** Dowsett M, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. *J Clin Oncol.* 2010;28(11):1829-34. **4.** Harris L, et al. ASCO 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol.* 2007;25(33):5287-5312. **5.** NCCN Clinical Practice Guidelines in Oncology™. Breast cancer. v1.2011. Available at: <http://www.nccn.org>, accessed December 6, 2010. **6.** Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol.* 2010;11(1):55-65. **7.** Data on file at Genomic Health Inc.



oncotype DX®
Breast Cancer Assay

Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc. American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network, NCCN, and NCCN Guidelines are trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy.
© 2011 Genomic Health, Inc. All rights reserved. GHI10042_0911